AlzeCure Pharma AB, a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, announced that the company’s presentation at the Alzheimer’s conference AD/PD 2023 is now available in its entirety on the company’s website.
